No validated molecular drug target

The term "No validated molecular drug target" is a placeholder designation used in pharmacological databases like ChEMBL and the Therapeutic Target Database (TTD) to indicate that the specific molecular entity—such as a receptor, enzyme, or ion channel—responsible for a drug's therapeutic effect has not been identified or confirmed (https://www.ebi.ac.uk/chembl/). This classification is common for drugs discovered through phenotypic screening, where the focus is on the physiological outcome rather than a specific protein interaction (https://pubmed.ncbi.nlm.nih.gov/21701501/). It may also apply to complex mixtures, traditional medicines, or older drugs where the polypharmacology or specific binding site is not yet characterized. Because no specific molecule is identified, standard target-based drug design and optimization strategies cannot be applied to these compounds. Understanding the target is crucial for modern drug development to predict side effects, improve potency, and identify potential drug-drug interactions (https://www.nature.com/articles/nrd3439). Consequently, this designation does not refer to a specific biological entity but rather a gap in current pharmacological knowledge that often represents a temporary state in the research lifecycle of a compound.

Other names

Unknown targetUnspecified targetMechanism of action unknownNon-molecular target

The mechanism of action is unknown, uncharacterized, or involves complex polypharmacology that has not been attributed to a single validated molecular target (https://www.nature.com/articles/nrd3439).